Director and Scientific Advisor
Ian currently serves as CEO of StemCells Inc. Previously he was co-founder & CEO of Synosia Therapeutics where he acquired a broad portfolio of clinical stage CNS therapeutics, raised multiple venture financings and led that company until its acquisition by Biotie Therapies in 2011. He held the role of Chief Operating Officer and President of US operations at Biotie until 2014. Prior to Synosia Ian held the roles of Senior VP Head of Research & Preclinical Development at Roche Palo Alto, VP Head of Neurobiology at Roche Bioscience, and VP of Preclinical Research at Syntex. Ian received his D.Phil (PhD) in Chemistry from Oxford University.
Clinical Pharmacy Pharmaceutical Administration Medicinal Chemistry